

Update on Pharmacoeconomics in the Irish Healthcare Setting



Date: 15th & 16th May 2019

Venue: Dublin Castle

DAY ONE

Registration and tea/coffee on arrival from 8.15 am

| DESCRIPTION | SPEAKER | TIME |
|---|--|--------------|
| Opening | Minister Simon Harris | 9.00 |
| Session 1 – Drugs for Rare Diseases: Recent Developments in | Assessment and Engagement | 9.30 |
| Equity in the Process: Assessment of Drugs for Rare Diseases | Prof Michael Barry | 20 mins |
| The Patient Perspective | Bernadette Gilroy, PKU Society | 20 mins |
| Overview of NCPE Patient Engagement Activities | Claire Gorry, NCPE | 30mins |
| Drugs for Rare Diseases: Submissions to the NCPE | Dr Cara Usher, NCPE | 20 mins |
| Coffee Break | | 11.00 |
| Session 2 - Assessing Advanced Therapeutic Medicinal Products – Perspectives and | | 11.30 |
| Considerations | | |
| Introduction to Advanced Therapy Medicinal Products | Dr Roisin Adams, NCPE | 20 mins |
| CAR-T therapies - The Clinical Perspective | Dr Larry Bacon, Consultant Haematologist, St James's Hospital | 40 mins |
| Institutional Requirements for the Provision of a CAR T-Cell Service: a HTA Review | Niamh Carey, NCPE | 30 mins |
| Lunch | | 13.00 |
| Session 3 – Future of HTA and Healthcare Funding - Stakeholder Perspectives | | 14.00 |
| National Centre for Pharmacoeconomics | Prof Michael Barry, Director of the NCPE | 20 mins |
| Irish Pharmaceutical Healthcare Association | Aidan Lynch, IPHA President | 20 mins |
| Drugs Group / National Cancer Control Programme | Dr Jerome Coffey, Director of the NCCP | 20 mins |
| Primary Care Reimbursement Service, HSE | Anne-Marie Hoey, Director of the PCRS | 20 mins |
| Acute Hospitals, HSE | Dr Roisin Adams, NCPE | 20 mins |
| Questions and Answers | All | 20 mins |
| Afternoon Close | | 16.00 |

Update on Pharmacoeconomics in the Irish Healthcare Setting



Date: 15th & 16th May 2019

Venue: Dublin Castle

DAY TWO

Tea/coffee on arrival from 8.15 am

| DESCRIPTION | SPEAKER | TIME |
|--|--|--------------|
| Session 1 – Recent Developments at the NCPE | | 9.00 |
| NCPE process update: Overview of NCPE Rapid Review / HTA Process | Dr Lesley Tilson, NCPE | 20 mins |
| An Analysis of Rapid Review and HTA Timelines | Emma Connolly, NCPE | 15 mins |
| Development of Plain English Summaries and Website Developments | Claire Gorry, NCPE | 15 mins |
| Budget Impact Template | Dr Felicity Lamrock, NCPE | 20 mins |
| NCPE Critical Appraisal of Economic Models | Dr Felicity Lamrock, NCPE | 15 mins |
| Tips for Improving the Quality of an Excel Model for Submission | Dr Joy Leahy, NCPE | 20 mins |
| Process for Internal Validation of Sensitivity Analysis | Dr Joy Leahy, NCPE | 15 mins |
| Coffee Break | | 11.00 |
| Session 2 – Research / Medicines Management Programme / European Initiatives | | 11.30 |
| Ongoing research at NCPE: | | |
| Cost effectiveness of Treatment Strategies for Skin Cancer | Claire Gorry, NCPE | 25 mins |
| Research in HTA methodology: Application to the PCSK9 inhibitors | Helen O'Donnell, NCPE | 25 mins |
| Update on Medicines Management Programme: | | 20 mins |
| Reimbursement Application System for the PCSK9 inhibitors | Prof Michael Barry, NCPE | |
| European Initiatives: | | 20 mins |
| Issues in Medicines Policy for 2019 | Dr Roisin Adams, NCPE | |
| Lunch | | 13.00 |
| Session 3 – NCPE HTA Discussion Group | | 14.00 |
| Issues arising from HTA submissions to the NCPE: disparities between the clinical trial and the Summary of Product Characteristics | Dr Laura McCullagh, Niamh Carey, Orla Maguire, Joanne O'Connor | 60 mins |
| Session 4 – HTA of Drugs with Limited Evidence | | 15.00 |
| Clinical Considerations | Dr Aisling O'Leary, NCPE | 20 mins |
| Statistical Considerations | Prof Cathal Walsh, Professor of Statistics, University of Limerick | 20 mins |
| How to appropriately include a Population Adjusted Indirect Comparison in a HTA Submission | Dr Joy Leahy, NCPE | 20 mins |
| Closing Remarks | Prof Michael Barry | 16.00 |